CASI PHARMACEUTICALS, INC. (CASIF) Return on equity 2020–2024
CASI PHARMACEUTICALS, INC. (CASIF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-2120.9%FY2024 · since FY2020: -59.2% → -2120.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -2120.9% | -2009.3 pp |
| FY2023 | -111.6% | -19.6 pp |
| FY2022 | -92.0% | -48.6 pp |
| FY2021 | -43.4% | +15.8 pp |
| FY2020 | -59.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CASIF financial trends
CASIF RevenueCASIF Net incomeCASIF Net marginCASIF Gross profitCASIF Gross marginCASIF Operating incomeCASIF Operating marginCASIF Operating cash flowCASIF Free cash flowCASIF Capital expendituresCASIF Stock buybacksCASIF Dividends paidCASIF Total assetsCASIF Total liabilitiesCASIF Shareholders’ equityCASIF overview →